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Amyloid  angiopathy  in  the  context  of hemodialysis:
An unknown  ﬁeld
Angiopatía  amiloide  en  el  contexto  de  hemodiálisis:
un  terreno  desconocido
Dear Editor:
It is known that cerebral amyloid angiopathy (CAA) is due
to amyloid beta peptide (A)  accumulation in the middle
and outer coats of small cerebral arteries and arterioles. CAA
irrupts as a intracranial hemorrhage, which can be a cere-
bral hematoma or multifocal microhemorrhages. It is difﬁcult
to estimate its real incidence because diagnosis conﬁrma-
tion requires an anatomopathological study, but it is rated
that almost 57% of non-traumatic intracranial hemorrhages in
patients between 71 and 80 years old might be caused by CAA.1
The spectrum of disease due to A includes several disorders.
In 1985, 2 microglobulin was identiﬁed as the responsible
of hemodialysis-associated amyloidosis.2 In the 1980 decade,
CAA was considered an Alzheimer’s disease subtype,3,4 and
they have been proposed as different conditions since the 1990
early decade.5 Therefore, CAA is a disease with its own entity,
but it lacks diagnosis, prevention and treatment protocols.
There is evidence that uremic environment and glomerular
ﬁltration rate decline in patients with chronic kidney disease,
aggravate cognitive functions and are related to microhe-
morrhages occurrence.6 Both, it is necessary to clarify to what
extent anticoagulant or antiplatelet treatments worsen CAA
evolution. In this regard, it is interesting the case of an 82 years
old patient with chronic kidney disease and hemodialysis for
four years, who was evaluated due to a 48 hours disorientation
state. His antecedents included memory  impairment for nine
years and an episode of multiple microangiopathic infarcts
eight years ago. Non-contrast head CT showed a right frontal
hematoma with perilesional edema, and hypodense lesions
located in periventricular and subcortical white matter and
left cerebellar hemisphere. That supported former infarcts or
hemorrhages. According to the Boston criteria,7 the patient
diagnosis was probable CAA.
rombotic therapy requirement. This is particularly importan
in patients under hemodialysis, who need anticoagulation
treatment during sessions. In regard to antiplatelet treatment
retrospective researches show different outcomes respecting
bleeding risk,8 although acetylsalicylic acid is generally avoi
ded and replaced by clopidogrel. Anticoagulation with heparin
is also controversial. On the one hand, a case report of CAA
related inﬂammation treated with enoxaparin 4000 IU/12 h
due to venous thrombosis, described a subsequent big cerebra
hematoma which caused death.9 On the other hand, low
molecular-weight heparin (LMWH) is recommended despite
cerebral hemorrhage if immobilization extends beyond 3–4
days.10 In the exposed case of the patient, LMWH  treatmen
was kept during hemodialysis sessions, and he continued hi
previous therapy with clopidogrel. Six days later, a contro
non-contrast head TC showed the resolution of acute hemorrThe deﬁciency of standardized strategies to detect CAA
and the bleeding risk that the disease entails, complicate
the management of concomitant pathologies with antith- Fig. 1Non-contrast head CT along hospitalization
(September 2015).
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Fig. 2FLAIR MRI  (December 2011) which showed
hyperintense lesions compatible with microhemorrhages.
hage, and due to the remarkable clinical improvement, the
patient was discharged from the hospital showing a normal
orientation state (Figs. 1 and 2).
Because of its signiﬁcance for hemodialysis patients, CAA
is an important disease in Nephrology sphere. It is already
known the importance of controlling parameters like arte-
rial pressure, anemia, or hydroelectrolytic equilibrium in those
patients in order to prevent microhemorrhages onset. Howe-
ver, prospective researches should focus on the bleeding
risk stratiﬁcation in CAA patients undergoing hemodialysis,
the impact of different antithrombotic treatments in those
patients, and emphasize diagnostic methods for CAA, like gra-
dient echo sequences MRI.
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